- Home
- ANVS
ANVS
Annovis Bio Inc.
as 07-26-2024 4:00pm EST
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 81.4M | IPO Year: | 2020 |
| Target Price: | $33.00 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.53 - $22.49 | Next Earning Date: | 08-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
GlobeNewswire
3 days ago
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
MT Newswires
10 days ago
Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form
GlobeNewswire
11 days ago
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
Zacks
14 days ago
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Zacks
16 days ago
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
Zacks
17 days ago
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
GlobeNewswire
18 days ago
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
Compare ANVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANVS Annovis Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.